Your browser doesn't support javascript.
loading
NEW-ONSET CARDIAC AMYLOIDOSIS WHILE IN REMISSION FROM SYSTEMIC AL AMYLOIDOSIS.
Idowu, Abiodun; Tung, Lillian; Chu, Catherine; Skeete, Jamario; Paner, Agne; Okwuosa, Tochukwu.
Afiliación
  • Idowu A; Department of Internal Medicine, Einstein Medical Center, Philadelphia, Pennsylvania, USA.
  • Tung L; Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
  • Chu C; Rush University Medical College, Chicago, Illinois, USA.
  • Skeete J; Division of Cardiology, Rush University Medical Center, Chicago, Illinois, USA.
  • Paner A; Division of Hematology/Oncology/Cell Therapy, Rush University Medical Center, Chicago, Illinois, USA.
  • Okwuosa T; Division of Cardiology, Section of Cardio-Oncology, Rush University Medical Center, Chicago, Illinois, USA.
Eur J Case Rep Intern Med ; 10(2): 003768, 2023.
Article en En | MEDLINE | ID: mdl-36970162
In light chain amyloidosis, a reduction in dFLC to below 40 mg/l is a prerequisite for organ recovery as nearly half of the patients who achieve very good partial haematological responses have improvement in the function of the involved organ. We describe a patient who developed new-onset cardiac amyloidosis despite a post-treatment reduction in dFLC to <10 mg/l. LEARNING POINTS: Patients with light chain (AL) amyloidosis may develop new cardiac involvement despite achieving haematological remission.In patients with AL amyloidosis, a very good partial haematological response (dFLC <10 mg/l) does not obviate the need for regular cardiac monitoring.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Eur J Case Rep Intern Med Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Eur J Case Rep Intern Med Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos